FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
Historical Prices
From:
To:
About
ceo
Dr. Jay R. Luly Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.enanta.comexchange
NASDAQ
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
CIK
0001177648
ISIN
US29251M1062
CUSIP
29251M106
Address
500 Arsenal Street
Phone
617 607 0800
Country
US
Employee
131
IPO Date
Mar 21, 2013
Financial Statement
Earnings
ENTA Financial Summary
CIK
0001177648
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
29251M106
ISIN
US29251M1062
Country
US
Price
6.65
Beta
0.48
Volume Avg.
539.27k
Market Cap
141.86M
Shares
-
52-Week
4.71-17.8
DCF
-7.91
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.34
P/B
-
Website
https://www.enanta.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ENTA News
Zacks Investment Research
Aug 5, 2024
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue ...
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.
Zacks Investment Research
Jul 15, 2024
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside ...
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Business Wire
May 29, 2024
Enanta Pharmaceuticals to Participate at the Jefferies Globa...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. A live webcast of the even.
Seeking Alpha
May 6, 2024
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Tr...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcom...
Zacks Investment Research
May 6, 2024
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue ...
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago.
Seeking Alpha
Feb 7, 2024
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Tr...
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Zacks Investment Research
Feb 7, 2024
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue ...
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.
Business Wire
Jan 31, 2024
Enanta Pharmaceuticals to Host Conference Call on February 7...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's bu.
